to dramatically improve the quality of life for a group of epilepsy patients for whom there is currently no effective treatment. CombiGene uses an adeno-associated viral vector (AAV) to administer a combination of neuropeptide Y (NPY) and its receptor Y2 directly to the part of the brain where the epileptic seizure begins. The most important preclinical effect studies have been concluded with positive results and the next step will be the compulsory safety studies. Given a positive outcome from the safety studies and successful GMP production of CG01, studies in humans can begin.